- Valneva Vaccine AstraZeneca jab . generated a stronger antibody response than
- The government pulled out of a £1.2bn deal for injections last month
- Trial leader said, ‘Vaccine can play an important role in controlling the epidemic’
French pharmaceutical firm Valneva today reported the successful results of its Covid vaccine trial – a month after Britain canceled its contract for 100 million doses.
The company said the vaccine produced a stronger antibody response than AstraZeneca’s rival JAB, when tested on thousands of Britons.
It also induced a strong T-cell response and triggered few side effects. No serious case of covid was observed among the recipients given the job.
Ministers last month withdrew their £1.2bn deal for 190 million doses of the vaccine, citing ‘breach of obligations’. Valneva ‘strongly’ denied the allegation.
Health Secretary Sajid Javid later said the contract was canceled for ‘commercial reasons’ and because the jab would not have been approved by the UK medicines watchdog.
But Professor Adam Finn, the trial’s principal investigator and member of the Joint Committee on Immunization and Immunization, which advises No. 10 on vaccine rollout, said the results show the jab is on track to play a key role in overcoming the pandemic. is on’.
And he said Valneva is ‘cautiously optimistic’ the vaccine will be approved in the UK by the end of this year, and it is not clear why Mr Javid has said so.
The biotech firm is manufacturing the vaccine at its plant in Livingston, West Lothian, which Boris Johnson visited in January.
The vaccine produced a stronger antibody response than AstraZeneca’s rival JAB when tested on thousands of Britons, the company said.
Graph shows antibody levels – scientifically known as geometric mean titre (GMT) – triggered by Valneva’s vaccine (left), AstraZeneca’s jab (right) on the first day (dark blue bar) ) and administered two weeks after the second dose. (light blue bar). Trials of 4,012 Britons found that the French-made vaccine produced an average of 39 percent more antibodies than those who received it by injection of AstraZeneca.
The trial’s principal investigator, Professor Adam Finn, said the results suggest Valneva’s jab is ‘on track to play a key role in containing the pandemic’
The covid-comparison trial involved 4,012 18- to 55-year-olds across the UK who were given the covid vaccine in two doses four weeks apart.
About two-thirds were given French-made injections, while the others were given AstraZeneca.
What do Valneva covid jab tests show?
Valneva has reported phase one, two and three clinical trial results for its coronavirus vaccine.
The most recent trial involved 4,012 British volunteers who received two doses of either Vulneva or AstraZeneca vaccines spaced two weeks apart.
Participants were asked to report any side effects, and had their blood tested for Covid antibodies two weeks after getting their second dose.
Does the jab trigger Covid-fighting antibodies?
The results showed that everyone who received the high dose of the jab had Covid antibodies in their bloodstream.
The company said the vaccine “demonstrated superiority” over the AstraZeneca vaccine.
Is Valneva vaccine safe?
The scientists said no safety concerns were raised during the earlier clinical trials, paving the way for its next phase.
Phase III found that the jabs were ‘generally well tolerated’ and that participants reported ‘significantly fewer’ side effects in the week following vaccination compared to the Oxford jab.
And no serious adverse events were recorded.
How does the vaccine work?
This vaccine is the only vaccine being developed in Europe that triggers an immune response using an inactivated whole COVID virus.
When it’s injected the body attacks the virus’s spike protein — which it uses to invade cells — by making antibodies that can bind to them, preventing infection from occurring.
The virus is killed before it is injected using chemicals, heat or radiation, which means it poses no risk of causing infection.
Such vaccines are already being used to protect against polio and flu.
What is the next step for the vaccine?
The company is in the process of asking the UK and the European Union to approve its vaccine.
The injection was also one of seven Covid vaccines included in the Cov-Boost trial.
The study, led by researchers from the University Hospital Southampton NHS Foundation Trust, aimed to determine which jab is most effective for a booster dose.
Valneva’s is also testing older adults in New Zealand and is preparing to test it on children between the ages of five and 12.
What was Valneva’s agreement with the UK?
The UK ordered 100 million doses from the French vaccine-maker in 2021 and 2022.
The contract allowed the UK to order an additional 90 million jobs between 2023 and 2025.
But Valneva announced in September that the government had terminated the contract, claiming the company had breached its obligations.
Blood samples were taken from the participants two weeks after their second jab.
In Phase III results released today, Valneva said its vaccine – called VLA2001 – “demonstrated superiority” over AstraZeneca by triggering 39 percent more neutralizing antibodies.
The company said its vaccine induced widespread T-cell responses, a part of the immune system believed to be involved in long-term immunity.
Side effects from the injection were ‘significantly more favorable’ that the comparator vaccine, with fewer people reporting a sore throat and other reactions.
One in 10 people will experience side effects after an AstraZeneca jab, such as arm pain, tiredness, and headache.
The number of Covid cases was similar among those given AstraZeneca or Valneva, suggesting they were just as effective.
And the ‘complete absence’ of any serious Covid cases in the group suggests that both vaccines provide protection against the currently circulating variants,…